Company intelligence / Profile preview

Proximos

Melbourne, Victoria, Australiaproximos.cz ↗

Ownership: Private
Development stage: Other

Overview

Proxima Bio is developing next-generation medicines using cell surface degraders to target previously undruggable disease-causing proteins. Their approach aims to provide new therapeutic options for autoimmune conditions and cancers. The company’s technology is preclinical, with no disclosed clinical results yet.

Therapeutic areas: ImmunologyOncology
Modalities: Small moleculeProtein degrader (cell surface degrader)
Industry: Biotech

Beyond the preview

Go deeper on Proximos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proximos.

Explore the full profile